EUVIMEDEUVIMED entdecken
Crossref

Two-year outcomes of half-fluence photodynamic therapy combined with intravitreal aflibercept for treatment-naïve pachychoroid neovasculopathy

Junki Hoshino, Hidetaka Matsumoto, Saki Numaga, Yosuke Asatori, Hideo Akiyama

Japanese Journal of Ophthalmology · 2025

DOI: 10.1007/s10384-025-01303-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Journal of Ophthalmology, 2025. Verfasst von Junki Hoshino und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins, Receptors, Vascular Endothelial Growth Factor, Photochemotherapy, Visual Acuity. Die Arbeit nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: We previously reported 1-year outcomes of half-fluence photodynamic therapy (HFPDT) combined with intravitreal aflibercept (IVA) in treatment-naïve pachychoroid neovasculopathy (PNV). In this study, we evaluated the 2-year outcomes of HFPDT combined with IVA in treatment-naïve PNV without polypoidal lesions. STUDY DESIGN: Retrospective, interventional case series METHODS: We retrospectively studied 61 eyes with treatment-naïve PNV that received HFPDT combined with IVA and were followed for at least 2 years. Additional treatments were given if a dry macula was not achieved or if exudation recurred. We evaluated the best-corrected visual acuity (BCVA), foveal thickness (FT), central choroidal thickness (CCT), and macular neovascularization thickness (MNVT). Factors associated with additional treatment were also analyzed. RESULTS: BCVA was significantly improved at 1 year (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Recombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorPhotochemotherapyVisual AcuityChoroidal NeovascularizationChoroidHumansRetrospective StudiesIntravitreal InjectionsMaleFemaleTomography, Optical CoherenceFluorescein AngiographyFollow-Up StudiesAgedFundus OculiTreatment OutcomeMiddle AgedAngiogenesis InhibitorsTime FactorsPhotosensitizing AgentsVerteporfinAged, 80 and over

Stichwörter der Autor:innen

AfliberceptAnti-vascular endothelial growth factorPachychoroid neovasculopathyPhotodynamic therapy

Substanzen

afliberceptRecombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorAngiogenesis InhibitorsPhotosensitizing AgentsVerteporfin

Autor:innen und Institutionen

  • Department of Ophthalmology, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
  • Department of Ophthalmology, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan. hide-m@gunma-u.ac.jp.

Zitieren

APA

Hoshino, J., Matsumoto, H., Numaga, S., Asatori, Y., & Akiyama, H. (2025). Two-year outcomes of half-fluence photodynamic therapy combined with intravitreal aflibercept for treatment-naïve pachychoroid neovasculopathy. Japanese Journal of Ophthalmology. https://doi.org/10.1007/s10384-025-01303-2

Vancouver

Hoshino J, Matsumoto H, Numaga S, Asatori Y, Akiyama H. Two-year outcomes of half-fluence photodynamic therapy combined with intravitreal aflibercept for treatment-naïve pachychoroid neovasculopathy. Japanese Journal of Ophthalmology. 2025. doi:10.1007/s10384-025-01303-2

BibTeX
@article{Hoshino2025,
  author = {Hoshino, Junki and Matsumoto, Hidetaka and Numaga, Saki and Asatori, Yosuke and Akiyama, Hideo},
  title = {Two-year outcomes of half-fluence photodynamic therapy combined with intravitreal aflibercept for treatment-naïve pachychoroid neovasculopathy},
  journal = {Japanese Journal of Ophthalmology},
  year = {2025},
  doi = {10.1007/s10384-025-01303-2}
}
Kostenlos starten →